Key result
Myostatin uniquely shows cardiac-specific loss- and gain-of-function evidence among mediators of heart failure muscle wasting.
Why the study?
Skeletal muscle wasting in heart failure is traditionally viewed as secondary to hypoperfusion, inactivity, and inflammation, leaving it unclear which circulating catabolic mediators rising with myocardial stress are demonstrably cardiac-derived versus unproven or unquantified in their cardiac contribution.
Clarifies that among major catabolic mediators associated with skeletal muscle wasting in heart failure, only myostatin has proven cardiac-specific loss- and gain-of-function evidence, highlighting the need for further validation before targeting this axis therapeutically.
Answers are grounded in this paper and cite their sources.
Questions cardiac origin of most HF muscle-wasting mediators; challenges consensus and leaves therapeutic targeting open pending direct validation.
Heart failure (HF) is frequently accompanied by skeletal muscle wasting, which is present in about one in five ambulatory patients and linked to reduced exercise capacity. It is traditionally viewed as secondary to hypoperfusion, inactivity, and inflammation, yet circulating mediators rising with myocardial stress also act on muscle, and some are released by the stressed heart. We examine heart-to-muscle signaling as a directional axis, distinguishing mediators whose circulating pool is demonstrably cardiac from those for which a cardiac contribution to the circulating pool is unproven or unquantified. Across five soluble mediators (growth differentiation factor 15, fibroblast growth factor 21, myostatin, angiotensin II and activin A) and cardiac extracellular vesicles, cardiac-specific loss- and gain-of-function evidence exists only for myostatin; for growth differentiation factor 15 and fibroblast growth factor 21, a dominant cardiac contribution to the circulating pool is unproven, so the axis is better termed cardiac-stress-associated than cardiac-derived. We link each mediator to the muscle phenotype and to therapies in trials, and define the arteriovenous-sampling and cardiac loss-of-function experiments needed before the axis can be considered a validated therapeutic target.
No takes yet. Share an insight, caveat, or question.
Vizzino et al. (2026) conducted a review in Heart failure accompanied by skeletal muscle wasting. Heart-to-muscle catabolic signaling mediators (GDF15, FGF21, myostatin, angiotensin II, activin A, and cardiac extracellular vesicles) was evaluated. Among 5 soluble catabolic mediators and extracellular vesicles evaluated in heart failure muscle wasting, only myostatin has cardiac-specific loss- and gain-of-function evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: